Anthem BioSciences Ltd (ANTH)

Currency in INR
825.65
0.00(0.00%)
Closed·
ANTH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
813.00837.00
52 wk Range
579.15873.50
Key Statistics
Bid/Ask
822.00 / 825.65
Prev. Close
825.65
Open
832.65
Day's Range
813-837
52 wk Range
579.15-873.5
Volume
799.26K
Average Volume (3m)
653.42K
1-Year Change
13.9614%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ANTH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
884.43
Upside
+7.12%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth

Anthem BioSciences Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 884.43
(+7.12% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy900.00+9.01%850.00MaintainJul 23, 2026
Nomura/Instinet
Buy900.00+9.01%740.00MaintainMay 22, 2026
JPMorgan
Buy850.00+2.95%790.00MaintainMay 21, 2026
Citi
Buy870.00+5.37%-New CoverageApr 21, 2026
JPMorgan
Buy790.00-4.32%780.00UpgradeFeb 09, 2026

Anthem BioSciences Ltd Earnings Call Summary for Q1/2027

  • Q1 FY2027 revenue fell to INR 418 crore due to delayed customer deliveries; EBITDA margin held strong at 39.6% with PAT margin at 27.1%
  • Stock declined 2.23% to $773.90 following softer quarterly results; shares remain 33.7% above 52-week low despite revenue timing concerns
  • Management expects revenue recovery in Q2-Q4 as deferred deliveries materialize; order book covers 60% of full-year FY2027 revenue needs
  • Company plans INR 700 crore CapEx for FY2027, mainly for Unit 4 expansion; phase 1 to cost INR 1,200 crore, completion expected by end of FY2028
  • New big pharma customer added in Q1; semaglutide API approval from CDSCO expected within 1-2 quarters to drive future growth
Last Updated: 07/22/2026, 03:14 PM
Read Full Transcript

Earnings

Latest Release
Jun 03, 2026
EPS / Forecast
3.40 / 2.20
Revenue / Forecast
6.11B / 4.83B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 10.11%
Dividend Yield
0.24%
Industry Median 0.67%
Annualized payout
2.00
Paid annually
5-Years Growth
-
Growth Streak

ANTH Income Statement

Compare ANTH to Peers and Sector

Metrics to compare
ANTH
Peers
Sector
Relationship
P/E Ratio
80.7x45.3x−0.4x
PEG Ratio
6.480.260.00
Price/Book
15.3x3.6x2.6x
Price / LTM Sales
23.2x5.1x3.0x
Upside (Analyst Target)
9.0%14.0%51.8%
Fair Value Upside
Unlock8.4%7.2%Unlock

Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to commercial manufacturing for small molecules and biologics. It also manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company was incorporated in 2006 and is based in Bengaluru, India.

Employees
2282
Market
India

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
69.72M12.38%57.57B
Other Institutional Investors
49.28M8.75%40.69B
Public Companies & Retail Investors
444.19M78.87%366.75B
Total
563.19M100.00%465B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Viridity Tone Llp3.78%21,313,79517,597,735
Portsmouth Technologies LLC2.73%15,396,32712,711,977

People Also Watch

3,260.60
ACUA
-0.68%
2,764.40
RRKA
-1.02%
3,656.20
AITN
+2.86%
408.15
BHEL
-1.03%

FAQ

What Is the Anthem BioSciences (ANTH) Stock Price Today?

The Anthem BioSciences stock price today is 825.65 INR.

What Stock Exchange Does Anthem BioSciences Trade On?

Anthem BioSciences is listed and trades on the India National Stock Exchange.

What Is the Stock Symbol for Anthem BioSciences?

The stock symbol for Anthem BioSciences is "ANTH."

Does Anthem BioSciences Pay Dividends? What’s The Current Dividend Yield?

The Anthem BioSciences dividend yield is 0.24%.

What Is the Anthem BioSciences Market Cap?

As of today, Anthem BioSciences market cap is 465.00B INR.

What Is Anthem BioSciences's Earnings Per Share (TTM)?

The Anthem BioSciences EPS (TTM) is 10.11.

When Is the Next Anthem BioSciences Earnings Date?

Anthem BioSciences will release its next earnings report on Sep 02, 2026.

From a Technical Analysis Perspective, Is ANTH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Anthem BioSciences Stock Split?

Anthem BioSciences has split 0 times.

How Many Employees Does Anthem BioSciences Have?

Anthem BioSciences has 2282 employees.

What is the current trading status of Anthem BioSciences (ANTH)?

As of Aug 06, 2026, Anthem BioSciences (ANTH) is trading at a price of 825.65 INR, with a previous close of 825.65 INR. The stock has fluctuated within a day range of 813.00 INR to 837.00 INR, while its 52-week range spans from 579.15 INR to 873.50 INR.

What Is Anthem BioSciences (ANTH) Price Target According to Analysts?

The average 12-month price target for Anthem BioSciences is 884.43 INR, with a high estimate of 941 INR and a low estimate of 830 INR. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +7.12% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.